DelveInsight sees hyperphosphatemia market growth through 2036 as new CKD therapies advance

The market research report points to rising chronic kidney disease and dialysis prevalence, with candidates including TS-172, AP-301, oxylanthanum carbonate and AP306 potentially reshaping treatment across the 7MM.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.